Pacira BioSciences (PCRX) FY2017 results: revenue $287 million, up 3.7% on the year
Pacira BioSciences, Inc. (PCRX) reported revenue of $287 million for fiscal 2017, the year ended 31 December 2017, up 3.7% on the year before. Net income was -$43 million, and diluted earnings per share $-1.07. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2018.
Revenue
$287 million
+3.7% on the year
FY2010FY2017
Operating margin
-8.7%
-11.6% a year earlier
FY2010FY2017
Net income
-$43 million
FY2010FY2017
Diluted EPS
-$1.07
FY2010FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
287
276
249
+3.7%
Cost of revenue
87.9
110
71.8
-20.2%
Gross profit
199
166
177
+19.5%
Gross margin
69.3%
60.2%
71.1%
Research and development
57.3
45.7
28.7
+25.4%
Selling, general and administrative
161
153
139
+5.8%
Operating income
-24.9
-32.0
9.5
Operating margin
-8.7%
-11.6%
3.8%
Interest expense
18.0
7.1
7.7
+155.6%
Pre-tax income
-42.5
-37.8
2.1
Income tax
0.1
0.1
0.3
+33.3%
Effective tax rate
n/a
n/a
12.5%
Net income
-42.6
-37.9
1.9
Net margin
-14.9%
-13.7%
0.7%
Diluted EPS
-$1.07
-$1.02
$0.04
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
17.8
33.5
28.0
-46.8%
Capital expenditure
19.3
24.7
40.3
-22.0%
Free cash flow
-1.5
8.7
-12.3
Free cash flow margin
-0.5%
3.2%
-4.9%
Cash from investing
-224
n/a
n/a
Cash from financing
224
n/a
n/a
Depreciation and amortisation
13.8
12.9
11.5
+7.1%
Share-based compensation
31.6
31.2
33.4
+1.1%
Diluted shares, weighted
40m
37m
41m
+6.9%
Shares outstanding at period end
41m
37m
37m
+8.5%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
279
219
218
+27.6%
Debt
276
109
104
+154.0%
Other liabilities
72.7
63.8
65.3
+14.1%
Total liabilities and equity
628
391
388
+60.5%
Fixed assets
107
101
90.3
+6.0%
Goodwill
55.2
46.7
30.9
+18.1%
Intangible assets
n/a
0.0
0.1
Investments
317
137
115
+132.2%
Cash and equivalents
54.1
35.9
57.0
+50.6%
Receivables
31.7
29.9
25.9
+5.7%
Inventory
41.4
31.3
61.6
+32.4%
Other assets
21.7
9.9
6.5
+118.8%
Total assets
628
391
388
+60.5%
10-K for the year ended 31 December 2017, filed 28 February 2018: the filing.